Clarametyx Biosciences has received approval from the Independent DMC to progress its Phase Ib/IIa trial of CMTX-101 ...

This space already includes two approved CAR T-cell therapies: Johnson & Johnson/Legend’s Carvykti and Bristol Myers Squibb’s ...

The US FDA has approved Ocugen’s IND amendment to commence a Phase II/III pivotal confirmatory study of OCU410ST.

Astria Therapeutics has reported encouraging initial outcomes from its ongoing ALPHA-SOLAR trial of navenibart for HAE ...

Data presented at EHA 2025 demonstrated that the Epkinly / R-ICE combination produced an 87% ORR in transplant-eligible r/r ...

At EHA 2025, the preliminary results from the global, multi-centre open-label non-randomised Phase II RedirecTT-1 clinical ...

Genmab has reported new outcomes from the Phase Ib/II EPCORE NHL-2 trial Arm 10 of T-cell engaging bispecific antibody, ...

Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...

Ionis Pharmaceuticals has dosed the first subject in the global, randomised Phase III REVEAL trial of investigational ION582.

Novartis has reported positive outcomes from the multicentre Phase IIIB APPULSE-PNH study of oral Fabhalta (iptacopan).

At the CTO West Coast conference, experts discussed the future of oncology clinical trials and key themes surrounding them.

MSD's Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...